MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.28
+0.70
+3.77%
After Hours: 21.30 +2.02 +10.48% 19:49 04/08 EDT
OPEN
18.77
PREV CLOSE
18.58
HIGH
19.34
LOW
18.09
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
29.61
52 WEEK LOW
4.260
MARKET CAP
1.40B
P/E (TTM)
-5.9748
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KPTI stock price target is 33.25 with a high estimate of 43.00 and a low estimate of 25.00.

EPS

KPTI News

More
  • Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
  • GlobeNewswire · 1d ago
  • Bristol-Myers Squibb to provide medicines to the unemployed and uninsured
  • Seeking Alpha - Article · 1d ago
  • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • GlobeNewswire · 04/01 21:05
  • Selloff creating bargains in healthcare - Baird
  • Seeking Alpha - Article · 03/25 17:54

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About KPTI

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
More

Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.